WE PERCEIVE. WE PREPARE. WE PROTECT.

Emergent Releases 2023 Environmental, Social, and Governance (ESG) Report

We are pleased to share Emergent’s 2023 Environmental, Social, and Governance (ESG) Report.  This report showcases our ESG priorities and the steps we’re taking to implement sustainable programing that meets the needs of our people and the communities we serve.

LEARN MORE

Continuing 25 years of protecting against public health threats

Whether it’s increasing access to NARCAN® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver vaccines and therapeutics, Emergent’s focus remains on protecting communities and addressing the evolving landscape of global health challenges.

LEARN MORE

Joseph C. Papa

Capabilities

We are a leader in providing solutions that address public health threats and bring lifesaving, life-extending products to market.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.

  • Bioservices

    Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.

Woman in Lab

At Emergent, our mission is to protect and enhance life.

View our 2023 Annual Report

Emergent BioSolutions Reports First Quarter 2024 Financial Results

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.
Read More

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business. Emergent will continue to focus on its core products business – medical countermeasures and NARCAN® Nasal Spray –and on delivering for its patients and customers, including the U.S. and allied governments.
Read More

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

GAITHERSBURG, Md., May 01, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more than 9 in 10 parents in the survey agree schools should do more to educate on the risks of opioids and how to respond to an overdose.
Read More
READ ALL NEWS

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.